[Healthkoreanews=seoul] Vaxcellbio, a company specializing in cancer immunotherapy (CEO Je Jung Lee), announced on the 10th that it has been granted a domestic patent for its jointly filed invention with Chonnam National University—titled “Monobody-Based Chimeric Antigen Receptor and Immune Cells Comprising the Same”.

The patent was granted approximately 2 years and 10 months after its initial filing in May 2022, increasing the company’s total number of registered patents to 12.

The newly registered patent covers a chimeric antigen receptor (CAR) technology that incorporates a monobody specifically binding to EphA2, a receptor known to be overexpressed in a wide range of solid tumors.

Compared to conventional antibodies, monobodies are tructurally simpler and more amenable to intracellular expression, making hem a promising alternative for next-generation CAR-based therapies.

With this patent, Vaxcellbio has secured a core technology for a CAR immune cell platform capable of precision targeting in solid tumors. Leveraging its proprietary library of monobodies specific to diverse tumor antigens, the company is actively developing VCB-1202, a next-generation monobody-based CAR immunotherapy targeting refractory solid tumors.

The patented technology will be integrated into Vaxcellbio’s broader CAR platform, accelerating the advancement of a robust therapeutic pipeline designed to ensure both efficacy and safety across various cancer types.

“This patent represents a key milestone that further validates the distinctiveness and competitiveness of Vaxcellbio’s CAR platform technology,” said CEO Je Jung Lee. “We are committed to pioneering new possibilities in solid tumor treatment based on our differentiated technology and to becoming a global leader in the immuno-oncology market”.

Vaxcellbio plans to actively leverage this patent to enhance its domestic and global intellectual property portfolio while pursuing open innovation strategies such as technology licensing, co-development, and global partnerships.